Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Gregory Lawrence Beatty

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7165-5993; OpenAlex author ID A5014753848; NIH RePORTER profile ID 9156575. Sources: OpenAlex.

Their work

Papers
32 (first author 4, last author 14)
Trials
0
Grants
6
Labs led
1
Collaborators
98
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: 2 grants · 2016: 1 paper · 2017: 5 papers, 1 grant · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers, 1 grant · 2022: none · 2023: 3 papers · 2024: 4 papers · 2025: 3 papers, 1 grant · 2026: 3 papers, 1 grant

Papers 32

  1. Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Last author DOI 10.1038/s41598-026-35423-7↗
  2. TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci.insight.195329↗
  3. HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Co-author DOI 10.64898/2026.10.02.754697↗
  4. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  5. Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/2025.05.22.655586↗
  6. Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2326-6066.cir-25-0575↗
  7. Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Last author DOI 10.1016/j.xcrm.2024.101397↗
  8. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2024.01.013↗
  9. Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer. Co-author DOI 10.1093/carcin/bgae065↗
  10. Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-2352↗
  11. Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Last author DOI 10.1038/s41467-023-41771-z↗
  12. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. First author DOI 10.1146/annurev-pathmechdis-031621-024600↗
  13. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltrat… Co-author DOI 10.1158/1078-0432.ccr-23-0535↗
  14. The biological underpinnings of therapeutic resistance in pancreatic cancer. Co-author DOI 10.1101/gad.348523.121↗
  15. Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. Last author DOI 10.1172/jci.insight.145389↗
  16. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
  17. Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. Last author DOI 10.1016/j.ebiom.2020.102662↗
  18. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Last author DOI 10.1016/j.ymthe.2020.07.017↗
  19. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Co-author DOI 10.1038/s41416-019-0582-7↗
  20. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. First author DOI 10.1016/j.pharmthera.2019.05.012↗
  21. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. First author DOI 10.1053/j.gastro.2018.12.038↗
  22. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Last author DOI 10.1007/s00262-017-2053-4↗
  23. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312078↗
  24. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-16-0870↗
  25. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-16-0899↗
  26. Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. Co-author DOI 10.1200/edbk_175232↗
  27. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application … Last author DOI 10.1002/cpph.2↗
  28. Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.4161/onci.28327↗
  29. CD40 immunotherapy for pancreatic cancer. Last author DOI 10.1007/s00262-013-1427-5↗
  30. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-13-1320↗
  31. Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.4161/onci.26837↗
  32. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. First author DOI 10.1016/j.ccr.2012.04.025↗

Grants 6

  1. Targeting the liver for immunotherapy in pancreatic cancer R01CA197916↗
  2. Combinatorial myeloid activation as immunotherapy for metastatic pancreatic cancer AWARD lustgarten:2025-gregory-beatty-combinatorial-myeloid-activation-as-immu
  3. Multiplex Tissue-based Assays and Analytical Tools for Pancreatic Cancer AWARD pancan:2021-gregory-l-beatty-md-phd-multiplex-tissue-based-assays-and-analyt
  4. Multiplex Tissue-based Assays and Analytical Tools for Pancreatic Cancer AWARD pancan:2017-gregory-beatty-multiplex-tissue-based-assays-and-analyt
  5. Immune escape mechanisms in metastatic pancreatic cancer AWARD pancan:2015-gregory-beatty-md-phd-immune-escape-mechanisms-in-metastatic-p
  6. CD40 Pathway in Pancreatic Adenocarcinoma K08CA138907↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Meredith L. Stone · 5 shared papers, 2019–2026 · strength 1.06
  2. Max Miller Wattenberg · 6 shared papers, 2020–2026 · strength 0.96
  3. Jae Woo Lee · 5 shared papers, 2016–2024 · strength 0.55
  4. John C. McVey · 2 shared papers, 2026 · strength 0.55
  5. Ben Z. Stanger · 3 shared papers, 2012–2026 · strength 0.48
  6. Robert H. Vonderheide · 5 shared papers, 2012–2026 · strength 0.48
  7. Kim A. Reiss · 3 shared papers, 2020–2026 · strength 0.48
  8. Elizabeth M. Jaffee · 1 shared paper, 2024 · strength 0.46
  9. Mara H. Sherman · 1 shared paper, 2023 · strength 0.39
  10. Stacy K. Thomas · 2 shared papers, 2020–2023 · strength 0.34
  11. Andrea Wang‐Gillam · 2 shared papers, 2023–2024 · strength 0.33
  12. Ignacio Garrido‐Laguna · 2 shared papers, 2023–2024 · strength 0.33
  13. Joey H. Li · 2 shared papers, 2023–2024 · strength 0.33
  14. Jacqueline Plesset · 1 shared paper, 2026 · strength 0.29
  15. Anna S. Thickens · 1 shared paper, 2026 · strength 0.29
  16. Diane M. Simeone · 2 shared papers, 2017–2021 · strength 0.26
  17. Nina G. Steele · 1 shared paper, 2026 · strength 0.22
  18. Debora Barbosa Vendramini Costa · 1 shared paper, 2026 · strength 0.22
  19. Naomi Yamamoto · 1 shared paper, 2026 · strength 0.22
  20. Ralph A. Francescone III · 1 shared paper, 2026 · strength 0.22
  21. Stephanie Dobersch · 1 shared paper, 2026 · strength 0.22
  22. Joana E. Aggrey-Fynn · 1 shared paper, 2026 · strength 0.22
  23. Ian M. Loveless · 1 shared paper, 2026 · strength 0.22
  24. Sita Kugel · 1 shared paper, 2026 · strength 0.22
  25. Adrianne Wallace-Povirk · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.